Kamada has secured a two-year extension from Canadian Blood Services to supply four specialty plasma-derived products—WinRho, HepaGam, CytoGam, and VariZIG—valued at $10–$14 million for the period between Q2-2026 and Q1-2028. The company reaffirmed its 2025 revenue guidance of $178–$182 million and adjusted EBITDA of $40–$44 million, and it is signaling double-digit growth in 2026 on the back of its commercial portfolio, Israeli biosimilar launches, and expanding plasma operations.
The contract is modest in absolute dollars, but strategically important. In a procurement landscape where supply assurance and clinical continuity outweigh marketing muscle, a renewed multi-product tender from a national buyer indicates stickiness in high-dependency hospital channels. It also underscores Kamada’s positioning as a consolidator of niche hyperimmune immunoglobulins—assets that are small individually but vital in aggregate and difficult to replace quickly due to donor sourcing, manufacturing complexity, and regulatory specificity.
This matters now because demand dynamics around hyperimmunes are shifting unevenly. In hepatitis B liver transplantation, broader uptake of potent antivirals has reduced long-term hepatitis B immune globulin use in some centers, yet short-course HBIG remains entrenched in many protocols. In CMV prophylaxis, letermovir has reshaped prevention practices, but immune globulin retains a role in select high-risk or adjunct settings. Rho(D) immune globulin continues as standard of care in obstetrics, and varicella zoster immune globulin remains necessary for post-exposure prophylaxis in vulnerable populations. For patients and clinicians, the extension signals continuity across these clinically critical, albeit niche, indications. For payers, it offers predictable access and budget visibility in categories where a stockout is far more costly than the unit price. For competitors, particularly larger plasma players, it effectively locks out a defined slice of the Canadian market for two years.
It also reflects a broader reset in plasma-derived therapeutics. After years of supply strain and price volatility, procurement agencies are prioritizing reliability and portfolio breadth over headline pricing. Manufacturers with integrated plasma collection capabilities and experience managing hyperimmune donor pools are better placed to meet those expectations. Kamada’s expansion of U.S. plasma collection and normal source plasma sales provides upstream leverage, while its proprietary and in-licensed hyperimmunes offer downstream differentiation. The company’s continued supply of anti-rabies immunoglobulin in Canada and the presence of Glassia, its alpha-1 antitrypsin therapy licensed to Takeda locally, further anchor its institutional relationships.
For Commercial leaders, the takeaway is that tender-centric markets reward operational credibility, portfolio bundling, and lifecycle defense more than traditional promotional tactics. The path to growth runs through multi-year agreements, supply performance, and selective business development that deepens the hospital bag. For Medical Affairs, the imperative is to generate contemporary real-world evidence and practice guidelines support that protect hyperimmune positioning against antiviral-only regimens and emerging monoclonal options, particularly in transplant and post-exposure prophylaxis where standards continue to evolve.
As governments push for greater plasma self-sufficiency and redundancy—Canada included, with procurement split between Canadian Blood Services and Héma-Québec—the competitive bar will rise on both supply security and clinical value demonstration. The next test for Kamada is whether it can replicate this template across Europe and other tender-heavy markets while defending utilization in indications where pharmacologic alternatives nibble at volume. The sharper question for the sector: in an era of antivirals and targeted antibodies, will hyperimmunes win on indispensability and reliability, or will innovation and policy gradually compress these legacy franchises into narrower, high-acuity niches?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
